Is Bristol Myers Squibb Stock Worth the Hype?
Join Anand Chokkavelu, Karl Thiel, and Keith Speights as they evaluate Bristol Myers Squibb (BMY) in the latest Motley Fool Scoreboard. Discover their ratings on the company’s business strength, management, financials, and valuation. Will this Big Pharma stock deliver returns or face challenges ahead? Tune in to find out!
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 838% as of 7/15/2025 and measured against the S&P 500 returns of 180% as of 7/15/2025. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
